<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INDOMETHACIN</span><br/>(in-doe-meth'a-sin)<br/><span class="topboxtradename">Indameth, </span><span class="topboxtradename">Indocid <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Indocin, </span><span class="topboxtradename">Indocin SR<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic, antipyretic</span>; <span class="classification">nsaid</span><br/><b>Prototype: </b>Ibuprofen<br/><b>Pregnancy Category: </b> B  (D in third trimester)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg capsules; 75 mg sustained release capsules; 25 mg/5 mL oral suspension; 50 mg suppositories; 1 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Potent nonsteroidal compound with antiinflammatory, analgesic, and antipyretic effects similar to those of aspirin. Appears
         to reduce motility of polymorphonuclear leukocytes, development of cellular exudates, and vascular permeability in injured
         tissue resulting in its antiinflammatory effects.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antipyretic and antiinflammatory actions may be related to its ability to inhibit prostaglandin biosynthesis. It is a potent
         analgesic.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative treatment in active stages of moderate to severe rheumatoid arthritis, ankylosing rheumatoid spondylitis, acute
         gouty arthritis, and osteoarthritis of hip in patients intolerant to or unresponsive to adequate trials with salicylates and
         other therapy. Also used IV to close patent ductus arteriosus in the premature infant.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To relieve biliary pain and dysmenorrhea, Paget's disease, athletic injuries, juvenile arthritis, idiopathic pericarditis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Allergy to indomethacin, aspirin, or other <small>NSAID</small>; nasal polyps associated with angioedema, history of GI lesions; pregnancy (category B; D in third trimester), lactation,
         children (<img src="../images/special/lesserorequal.gif"/>14 y).
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of psychiatric illness, epilepsy, parkinsonism; impaired renal or hepatic function; uncontrolled infections; coagulation
         defects, CHF; older adults, persons in hazardous occupations.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Rheumatoid Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2550 mg b.i.d or t.i.d. (max: 200 mg/d) or 75 mg sustained release 12 times/d<br/><br/><span class="indicationtitle">Pediatric Arthritis</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 12 mg/kg/d in 24 divided doses (max: 4 mg/kg/d) or 150200 mg/d<br/><br/><span class="indicationtitle">Acute Gouty Arthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/PR</span> 50 mg t.i.d. until pain is tolerable, then rapidly taper<br/><br/><span class="indicationtitle">Bursitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2550 mg t.i.d. or q.i.d. (max: 200 mg/d) or 75 mg sustained release 12 times/d<br/><br/><span class="indicationtitle">Close Patent Ductus Arteriosus</span><br/><span class="rdage">Premature neonate:</span> <span class="rdroute">IV</span> <i>, 0.2 mg/kg followed by 2 doses of 0.1 mg/kg q1224h; <i>27 d</i>, 0.2 mg/kg followed by 2 doses of 0.2 mg/kg q1224h; <i>, 0.2 mg/kg followed by 2 doses of 0.25 mg/kg q1224h<br/></i></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give immediately after meals, or with food, milk, or antacid (if prescribed) to minimize GI side effects.</li>
</ul><span class="adminroutetype">Rectal</span><br/><ul>
<li>Indomethacin rectal suppository use is contraindicated with history of proctitis or recent bleeding.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute 1 mg with 1 mL of NS or sterile water for injection without preservatives. Resulting concentration (1 mg/mL) may be
                  further diluted with an additional 1 mL for each 1 mg to yield 0.5 mg/mL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give by direct IV with a single dose given over 510 s.  
               </p>
<ul>
<li>Avoid extravasation or leakage; drug can be irritating to tissue.</li>
<li>Discard any unused drug, since it contains no preservative.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store oral and rectal forms in tight, light-resistant containers unless otherwise directed. Do not freeze.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (rash, purpura, pruritus, urticaria, angioedema, angiitis, rapid fall in blood pressure, dyspnea, asthma
      syndrome in aspirin-sensitive patients), edema, weight gain, flushing, sweating. <span class="typehead">CNS:</span> Headache, <span class="speceff-common">dizziness,</span> vertigo, light-headedness, syncope, fatigue, muscle weakness, ataxia, insomnia, nightmares, drowsiness, confusion, coma,
      convulsions, peripheral neuropathy, psychic disturbances (hallucinations, depersonalization, depression), aggravation of epilepsy,
      parkinsonism. <span class="typehead">CV:</span> Elevated BP, palpitation, chest pains, tachycardia, bradycardia, CHF. <span class="typehead">Special Senses:</span> Blurred vision, lacrimation, eye pain, visual field changes, corneal deposits, retinal disturbances including macula, <span class="speceff-common">tinnitus,</span> hearing disturbances, epistaxis. <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting,</span> diarrhea, anorexia, bloating, abdominal distention, ulcerative stomatitis, proctitis, rectal bleeding, <span class="speceff-life">GI ulceration, hemorrhage, perforation, toxic hepatitis</span>. <span class="typehead">Hematologic:</span> Hemolytic anemia, <span class="speceff-life">aplastic anemia</span> (sometimes fatal), <span class="speceff-life">agranulocytosis</span>, leukopenia, thrombocytopenic purpura, inhibited platelet aggregation. <span class="typehead">Urogenital:</span> Renal function impairment, hematuria, urinary frequency; vaginal bleeding, breast changes. <span class="typehead">Skin:</span> Hair loss, exfoliative dermatitis, erythema nodosum, tissue irritation with extravasation. <span class="typehead">Metabolic:</span> Hyponatremia, hypokalemia, hyperkalemia, hypoglycemia or hyperglycemia, glycosuria (rare). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Increased <span class="alt">AST,</span> <span class="alt">ALT,</span> <span class="alt">bilirubin,</span> <span class="alt">BUN;</span> positive direct <span class="alt">Coombs' test.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">oral anticoagulants</span>, <b>heparin,</b> <b>alcohol</b> may prolong bleeding time; may increase <b>lithium</b> toxicity; effects of <span class="classification">oral anticoagulants</span>, <b>phenytoin,</b> <span class="classification">salicylates</span>, <span class="classification">sulfonamides</span>, <span class="classification">sulfonylureas</span> increased because of protein-binding displacement; increased toxicity including GI bleeding with <span class="classification">salicylates</span>, <span class="classification">nsaid</span>s; may blunt effects of <span class="classification">antihypertensives</span> and <span class="classification">diuretics</span>. <span class="typehead">Herbal:</span> <b>Feverfew,</b> <b>garlic,</b> <b>ginger,</b> <b>ginkgo</b> may increase bleeding potential. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Completely absorbed from GI tract. <span class="typehead">Onset:</span> 12 h. <span class="typehead">Peak:</span> 3 h. <span class="typehead">Duration:</span> 46 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 2.5124 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: In acute gouty attack, relief of joint tenderness and pain is usually apparent in 2436
            h; swelling generally disappears in 35 d. In rheumatoid arthritis: Reduced fever, increased strength, reduced stiffness,
            and relief of pain, swelling, and tenderness.
         </li>
<li>Question patient carefully regarding aspirin sensitivity before initiation of therapy.</li>
<li>Observe patients carefully; instruct to report adverse reactions promptly to prevent serious and sometimes irreversible or
            fatal effects.
         </li>
<li>Lab tests: Monitor renal function, hepatic function, CBC with differential, BP and HR, visual and hearing acuity periodically.</li>
<li>Monitor weight and observe dependent areas for signs of edema in patients with underlying cardiovascular disease.</li>
<li>Monitor I&amp;O closely and keep physician informed during IV administration for patent ductus arteriosus. Significant impairment
            of renal function is possible; urine output may decrease by 50% or more. Also monitor BUN, serum creatinine, glomerular
            filtration rate, creatinine clearance, and serum electrolytes.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of S&amp;S of GI bleeding, visual disturbance, tinnitus, weight gain, or edema.</li>
<li>Do not take aspirin or other <small>NSAID</small>s; they increase possibility of ulcers.
         </li>
<li> 							Note: Frontal headache is the most frequent CNS adverse effect; if it persists, dosage reduction or drug withdrawal may be indicated.
            Take drug at bedtime with milk to reduce the incidence of morning headache. 						
         </li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>